PPD TOMORROW

De MORGEN studie AC-055-312 betrokkenheid App.

The TOMORROW study AC-055-312 engagement App has been developed to engage patients in the event-driven study to assess efficacy, safety and pharmacokinetics of macitentan versus standard of care in children with pulmonary arterial hypertension.

The App will look to engage patients registered into this study.

*Note: this App requires an activation code and can only be accessed by patients who are participating in the AC-055-312 trial.

“This app is to support an approved observational research study.”